Citius Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.19 Insider Own8.40% Shs Outstand146.21M Perf Week17.45%
Market Cap165.51M Forward P/E1.22 EPS next Y0.96 Insider Trans0.00% Shs Float133.82M Perf Month0.86%
Income-28.00M PEG- EPS next Q-0.04 Inst Own11.10% Short Float / Ratio8.56% / 13.75 Perf Quarter48.99%
Sales- P/S- EPS this Y-2.10% Inst Trans-8.45% Short Interest11.45M Perf Half Y-3.31%
Book/sh0.69 P/B1.70 EPS next Y123.30% ROA-23.60% Target Price7.00 Perf Year-34.64%
Cash/sh0.26 P/C4.49 EPS next 5Y- ROE-26.00% 52W Range0.77 - 2.01 Perf YTD48.10%
Dividend- P/FCF- EPS past 5Y34.40% ROI- 52W High-41.79% Beta1.40
Dividend %- Quick Ratio9.30 Sales past 5Y- Gross Margin- 52W Low51.95% ATR0.07
Employees21 Current Ratio9.30 Sales Q/Q- Oper. Margin- RSI (14)58.90 Volatility6.24% 6.52%
OptionableYes Debt/Eq0.00 EPS Q/Q61.10% Profit Margin- Rel Volume1.09 Prev Close1.10
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume832.65K Price1.17
Recom2.00 SMA2011.58% SMA50-2.05% SMA2006.15% Volume934,391 Change6.36%
Nov-30-21Initiated Maxim Group Buy $4
Mar-30-23 08:30AM
Mar-27-23 09:52AM
Mar-13-23 09:15AM
Mar-08-23 08:30AM
Feb-10-23 04:30PM
10:30AM Loading…
Feb-06-23 10:30AM
Jan-17-23 10:00AM
Jan-16-23 07:09AM
Jan-11-23 08:30AM
Dec-28-22 09:35AM
Dec-22-22 04:30PM
Dec-01-22 07:30AM
Nov-21-22 08:00AM
Nov-09-22 08:30AM
Oct-18-22 08:30AM
07:59AM Loading…
Oct-06-22 04:30PM
Sep-28-22 08:30AM
Sep-23-22 06:48AM
Sep-22-22 04:30PM
Sep-15-22 08:30AM
Sep-08-22 04:30PM
Sep-07-22 08:30AM
Aug-11-22 04:31PM
Aug-09-22 07:24AM
Jul-12-22 08:07AM
May-25-22 10:13AM
May-18-22 09:30AM
May-12-22 04:30PM
07:34AM Loading…
May-11-22 07:34AM
May-10-22 11:10AM
May-08-22 09:00AM
May-06-22 09:37AM
May-03-22 10:06AM
Apr-26-22 08:30AM
Apr-14-22 09:25AM
Apr-13-22 09:25AM
Apr-07-22 09:57AM
Apr-06-22 08:14AM
Mar-29-22 10:18AM
Mar-03-22 09:15AM
Mar-02-22 04:12AM
Feb-15-22 09:15AM
Feb-10-22 04:30PM
Jan-04-22 09:00AM
Dec-15-21 04:30PM
Dec-06-21 09:15AM
Dec-02-21 05:17AM
Nov-05-21 09:15AM
Oct-25-21 09:15AM
Oct-13-21 11:38AM
Oct-06-21 10:40AM
Oct-04-21 12:31PM
Oct-01-21 08:30AM
Sep-23-21 12:12PM
Sep-16-21 10:38AM
Sep-14-21 10:06AM
Sep-08-21 11:34AM
Sep-07-21 07:30AM
Aug-12-21 04:30PM
Aug-04-21 10:34AM
Aug-03-21 04:29PM
Jul-20-21 07:17AM
Jul-07-21 07:15PM
Jul-01-21 12:56PM
Jun-23-21 07:51AM
Jun-21-21 06:50PM
Jun-17-21 06:00AM
Jun-16-21 05:55PM
Jun-15-21 09:20AM
Jun-08-21 02:11PM
Jun-07-21 09:00AM
Jun-03-21 08:18AM
May-25-21 02:52PM
May-18-21 09:29AM
May-17-21 12:30PM
May-13-21 07:30AM
May-11-21 04:30PM
May-04-21 09:15AM
Apr-29-21 09:37AM
Apr-22-21 04:30PM
Apr-19-21 08:53AM
Mar-23-21 09:00AM
Mar-04-21 10:11AM
Feb-19-21 04:47PM
Feb-17-21 12:28AM
Feb-16-21 09:15AM
Feb-08-21 08:35AM
Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.